5v43 - Revision history

OCA at 12:53, 6 November 2017

OCA — Mon, 06 Nov 2017 12:53:57 GMT

←Older revision		Revision as of 12:53, 6 November 2017
Line 3:		Line 3:
	<StructureSection load='5v43' size='340' side='right' caption='[[5v43]], [[Resolution\|resolution]] 2.32Å' scene=''>		<StructureSection load='5v43' size='340' side='right' caption='[[5v43]], [[Resolution\|resolution]] 2.32Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5v43]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V43 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5V43 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5v43]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V43 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5V43 FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5v43 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v43 OCA], [http://pdbe.org/5v43 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5v43 RCSB], [http://www.ebi.ac.uk/pdbsum/5v43 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5v43 ProSAT]</span></td></tr>	+	</td></tr><tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">IGHG1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5v43 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v43 OCA], [http://pdbe.org/5v43 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5v43 RCSB], [http://www.ebi.ac.uk/pdbsum/5v43 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5v43 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 21:		Line 22:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Marshall, N]]		[[Category: Marshall, N]]
	[[Category: Yan, W]]		[[Category: Yan, W]]

OCA at 10:24, 3 August 2017

OCA — Thu, 03 Aug 2017 10:24:05 GMT

←Older revision		Revision as of 10:24, 3 August 2017
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5v43 is ~~ON HOLD until Paper~~ Publication	+	==Engineered human IgG Fc domain aglyco801==
		+	<StructureSection load='5v43' size='340' side='right' caption='[[5v43]], [[Resolution\|resolution]] 2.32Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5v43]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V43 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5V43 FirstGlance]. <br>
		+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5v43 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v43 OCA], [http://pdbe.org/5v43 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5v43 RCSB], [http://www.ebi.ac.uk/pdbsum/5v43 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5v43 ProSAT]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/IGHG1_HUMAN IGHG1_HUMAN]] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:[http://omim.org/entry/254500 254500]]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Engineered crystallizable fragment (Fc) regions of antibody domains, which assume a unique and unprecedented asymmetric structure within the homodimeric Fc polypeptide, enable completely selective binding to the complement component C1q and activation of complement via the classical pathway without any concomitant engagement of the Fcgamma receptor (FcgammaR). We used the engineered Fc domains to demonstrate in vitro and in mouse models that for therapeutic antibodies, complement-dependent cell-mediated cytotoxicity (CDCC) and complement-dependent cell-mediated phagocytosis (CDCP) by immunological effector molecules mediated the clearance of target cells with kinetics and efficacy comparable to those of the FcgammaR-dependent effector functions that are much better studied, while they circumvented certain adverse reactions associated with FcgammaR engagement. Collectively, our data highlight the importance of CDCC and CDCP in monoclonal-antibody function and provide an experimental approach for delineating the effect of complement-dependent effector-cell engagement in various therapeutic settings.

-	~~Authors~~:	+	IgG Fc domains that bind C1q but not effector Fcgamma receptors delineate the importance of complement-mediated effector functions.,Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, Lux A, Marshall N, Lindorfer MA, Goff OR, Balbino B, Kang TH, Tanno H, Delidakis G, Alford C, Taylor RP, Nimmerjahn F, Varadarajan N, Bruhns P, Zhang YJ, Georgiou G Nat Immunol. 2017 Aug;18(8):889-898. doi: 10.1038/ni.3770. Epub 2017 Jun 12. PMID:28604720<ref>PMID:28604720</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
		+	<div class="pdbe-citations 5v43" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Marshall, N]]
		+	[[Category: Yan, W]]
		+	[[Category: Zhang, Y J]]
		+	[[Category: Antibody engineering]]
		+	[[Category: Fc fragment]]
		+	[[Category: Immune system]]

OCA at 11:34, 5 April 2017

OCA — Wed, 05 Apr 2017 11:34:26 GMT

←Older revision		Revision as of 11:34, 5 April 2017
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5v43 is ON HOLD	+	The entry 5v43 is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "5v43" [edit=sysop:move=sysop]

OCA — Wed, 15 Mar 2017 19:44:32 GMT

Protected "5v43" [edit=sysop:move=sysop]

←Older revision

Revision as of 19:44, 15 March 2017

OCA: New page: '''Unreleased structure''' The entry 5v43 is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 15 Mar 2017 19:44:31 GMT

New page: '''Unreleased structure''' The entry 5v43 is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 5v43 is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]